TY - JOUR T1 - Neuropsychiatric copy number variants exert shared effects on human brain structure JF - medRxiv DO - 10.1101/2020.04.15.20056531 SP - 2020.04.15.20056531 AU - Claudia Modenato AU - Kuldeep Kumar AU - Clara Moreau AU - Sandra Martin-Brevet AU - Guillaume Huguet AU - Catherine Schramm AU - Jean-Louis Martineau AU - Charles-Olivier Martin AU - Nadine Younis AU - Petra Tamer AU - Elise Douard AU - Fanny Thébault-Dagher AU - V. Côté AU - A.R. Charlebois AU - F. Deguire AU - Anne M. Maillard AU - Borja Rodriguez-Herreros AU - Aurèlie Pain AU - Sonia Richetin AU - 16p11.2 European Consortium AU - Simons Variation in Individuals Project (VIP) Consortium AU - Leila Kushan AU - Lester Melie-Garcia AU - Ana I. Silva AU - Marianne B.M. van den Bree AU - David E.J. Linden AU - Michael J. Owen AU - Jeremy Hall AU - Sarah Lippé AU - Mallar Chakravarty AU - Danilo Bzdok AU - Carrie E. Bearden AU - Bogdan Draganski AU - Sébastien Jacquemont Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/17/2020.04.15.20056531.abstract N2 - Background Copy Number Variants (CNVs) associated with autism and schizophrenia have large effects on brain anatomy. Yet, neuroimaging studies have been conducted one mutation at a time. We hypothesize that neuropsychiatric CNVs may exert general effects on brain morphometry because they confer risk for overlapping psychiatric conditions.Methods We analyzed T1-weighted MRIs and characterized shared patterns on brain anatomy across 8 neuropsychiatric CNVs. Clinically ascertained samples included 1q21.1 (n=48), 16p11.2 (n=156), or 22q11.2 (n=96) and 331 non-carriers. Non-clinically ascertained samples from the UK Biobank included 1q21.1 (n=19), 16p11.2 (n=8), 22q11.2 (n=9), 15q11.2 (n=148) and 965 non-carriers. Canonical correlation analysis (CCA) and univariate models were used to interrogate brain morphometry changes across 8 CNVs.Results Eight CNVs affect regional brain volumes along two main gene-morphometry dimensions identified by CCA. While fronto-temporal regions contributed to dimension 1, dimension 2 was driven by subcortical, parietal and occipital regions. Consistently, voxel-wise whole-brain analyses identified the same regions involved in patterns of alteration present across the 4 deletions and duplications. These neuroanatomical patterns are similar to those observed in cross-psychiatric disorder meta-analyses. Deletions and duplications at all 4 loci show mirror effects at either the global and/or the regional level.Conclusion Neuropsychiatric CNVs share neuroanatomical signatures characterized by a parsimonious set of brain dimensions. The latter may underlie the risk conferred by CNVs for a similar spectrum of neuropsychiatric conditions.Competing Interest StatementMvdB reports grants from Takeda Pharmaceuticals, outside the submitted work.Funding StatementThis research was supported by Calcul Quebec (http://www.calculquebec.ca) and Compute Canada (http://www.computecanada.ca), the Brain Canada Multi-Investigator initiative, the Canadian Institutes of Health Research, CIHR_400528, The Institute of Data Valorization (IVADO) through the Canada First Research Excellence Fund, Healthy Brains for Healthy Lives through the Canada First Research Excellence Fund. Dr Jacquemont is a recipient of a Canada Research Chair in neurodevelopmental disorders, and a chair from the Jeanne et Jean Louis Levesque Foundation. The Cardiff CNV cohort was supported by the Wellcome Trust Strategic Award “DEFINE” and the National Centre for Mental Health with funds from Health and Care Research Wales (code 100202/Z/12/Z). The CHUV cohort was supported by the SNF (Maillard Anne, Project, PMPDP3 171331). Data from the UCLA cohort provided by Dr. Bearden (participants with 22q11.2 deletions or duplications and controls) was supported through grants from the NIH (U54EB020403), NIMH (R01MH085953, R01MH100900, R03MH105808), and the Simons Foundation (SFARI Explorer Award). Claudia Modenato was supported by the doc.mobility grant provided by the Swiss National Science Foundation (SNSF). Kuldeep Kumar was supported by The Institute of Data Valorization (IVADO) Postdoctoral Fellowship program, through the Canada First Research Excellence Fund. Dr. Bzdok was supported by the Healthy Brains Healthy Lives initiative (Canada First Research Excellence fund), and by the CIFAR Artificial Intelligence Chairs program (Canada Institute for Advanced Research).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOverlap maps are available through a request to the corresponding authors. ER -